Responses
Clinical/translational cancer immunotherapy
The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation
Compose a Response to This Article
Other responses
No responses have been published for this article.
